324 related articles for article (PubMed ID: 23674603)
1. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
2. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
3. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
4. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
5. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Furue M; Kadono T; Tsuji G; Nakahara T
Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
[TBL] [Abstract][Full Text] [Related]
6. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
[TBL] [Abstract][Full Text] [Related]
7. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
Ohba F; Nomoto M; Hojo S; Akama H
J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
[TBL] [Abstract][Full Text] [Related]
11. Topical Application of a PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL-4 Production.
Takahashi K; Miyake K; Ito J; Shimamura H; Suenaga T; Karasuyama H; Ohashi K
J Invest Dermatol; 2024 May; 144(5):1048-1057.e8. PubMed ID: 37827277
[TBL] [Abstract][Full Text] [Related]
12. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Ishii N; Wakita H; Shirato M
J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
[No Abstract] [Full Text] [Related]
13. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A
J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585
[No Abstract] [Full Text] [Related]
15. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Ahluwalia J; Udkoff J; Waldman A; Borok J; Eichenfield LF
Drugs; 2017 Sep; 77(13):1389-1397. PubMed ID: 28681318
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
[TBL] [Abstract][Full Text] [Related]
17. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Harada D; Takada C; Nosaka Y; Takashima Y; Kobayashi K; Takaba K; Manabe H
Int Immunopharmacol; 2009 Jan; 9(1):55-62. PubMed ID: 18854230
[TBL] [Abstract][Full Text] [Related]
18. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
19. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
20. Effects of topically applied Korean red ginseng and its genuine constituents on atopic dermatitis-like skin lesions in NC/Nga mice.
Kim HS; Kim DH; Kim BK; Yoon SK; Kim MH; Lee JY; Kim HO; Park YM
Int Immunopharmacol; 2011 Feb; 11(2):280-5. PubMed ID: 21118672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
